加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.9788
+US$0.0057 · +0.59%
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
前收盘价
US$0.9788
+US$0.0057 · +0.59%
盘中时间采用ET。市场数据可能有所延迟。
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
日内区间
当前US$0.9788
52周区间
当前US$0.9788
盘中时间采用ET。市场数据可能有所延迟。
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
日内区间
当前US$0.9788
52周区间
当前US$0.9788
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 461.8万 USD | 364.3万 USD | 633.2万 USD | 701.2万 USD | 888.6万 USD |
| 毛利 | −461.8万 USD | −364.3万 USD | −633.2万 USD | −701.2万 USD | −888.6万 USD |
| 研究与开发 | 461.8万 USD | 364.3万 USD | 633.2万 USD | 701.2万 USD | 888.6万 USD |
| 销售、一般及管理费用 | 460.2万 USD | 374.4万 USD | 428.8万 USD | 445万 USD | 462.5万 USD |
| 营业费用 | 460.2万 USD | 374.4万 USD | 449.2万 USD | 445万 USD | 462.5万 USD |
| 利息收入 | — | 23.1万 USD | — | — | — |
| 折旧和摊销 | 3000 USD | 3.5万 USD | 18.4万 USD | 19.3万 USD | 7.5万 USD |
| 营业利润 | −922万 USD | −738.7万 USD | −1082.4万 USD | −1146.2万 USD | −1351.1万 USD |
| 净利润 | −869.8万 USD | −715万 USD | −1082.6万 USD | −1148万 USD | −1328.7万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
